Measures in the first year of therapy predict the response to interferon β in MS
about
Current status of biomarker research in neurologyOptimizing treatment success in multiple sclerosisClinical correlates of grey matter pathology in multiple sclerosisRevised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple SclerosisGuidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients.MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple SclerosisClinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques.Therapeutic strategies in childhood multiple sclerosisInterleukin 17F level and interferon β response in patients with multiple sclerosis.Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.Risk acceptance in multiple sclerosis patients on natalizumab treatment.Relapsing-remitting multiple sclerosis: patterns of response to disease-modifying therapies and associated factors: a national survey.NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.Utility of the rio score and modified rio score in korean patients with multiple sclerosis.Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimodMRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort.Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple SclerosisActivation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.Predictors of disease activity in 857 patients with MS treated with interferon beta-1bCurrent and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.Defining Disease Activity and Response to Therapy in MS.Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisTRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic responseLong-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.Initiating oral fingolimod treatment in patients with multiple sclerosisSafety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.Assessing treatment response to interferon-β: is there a role for MRI?Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.Determinants of interferon β efficacy in patients with multiple sclerosis.Contribution of magnetic resonance imaging to the diagnosis and monitoring of multiple sclerosis.Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO.Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice.
P2860
Q26744505-4EAF5A35-83F7-4B6A-BD24-9BE24521BB6BQ26771968-502DB457-E4B8-44A5-BD7D-62735ACD5F54Q26999302-273B01B8-E22E-41A9-944F-D26D119B02C1Q30278095-333DA553-B5A6-4200-954A-4F5B7694FE84Q30653549-0ABD327A-876D-4409-9F1F-39B06E0F391AQ30981999-597A94DA-B0AD-471D-AF02-C5CEB3F54CACQ33755345-598E0355-36FE-4961-B4CC-0E80573AA2F4Q33830080-7D7877FC-2F2F-4149-9742-036DEEC5E772Q34053077-A0002709-2C25-41FD-93FA-B09CA355C4C1Q34171891-EA3AAC3F-6554-4F5B-AF50-EF55E1839CA8Q34409508-A70D12B5-62CF-4682-ADC1-624ABA80DDF7Q34915610-84F1A807-4FF7-4F7E-847C-AEF7836D2880Q35030123-32048AD3-625A-41F5-8A94-C6E6916178FEQ35067882-9E8B7164-6E76-451B-9D3F-A90BB6587DC2Q35280670-7DE1629B-3D3A-48A0-9C4A-2FD91C5EC3DDQ35533948-1D0953C6-C800-48CF-9FAF-ECDBF3F2036CQ35641688-F8D8701E-9D39-4E21-825F-7941F37D4B4EQ36097847-D312989E-9C8E-4F74-B160-B509EFE405A9Q36141526-12DB2740-77A6-4D5F-BB6D-57595A1ED1C1Q36247618-66C7BBE4-5E05-4EF1-A519-C2BBB0C8305AQ36253827-EAADDA39-37CB-43DB-B391-FDC4B6D390A2Q36265324-AFEBA3F5-33C6-4E2E-A4C3-84588EDBC459Q36352813-B8487604-6F60-419D-A6D2-017B8F88EDB9Q36357501-00B4862B-B6F7-498B-9601-FE42C01C72EAQ36359388-53193786-76CB-4894-B053-E7FCF4E8CBECQ36400004-030532F6-E5F9-495F-9A20-587B0D0EFFB8Q36484448-5B6A2AF1-A161-413B-854C-11DC7539C95AQ36577263-A6C195E0-9435-494D-85CB-20EF2FA624F3Q36859528-C891577E-45F5-407D-9FBE-4B92EC2D26A9Q36999746-10954A1B-7127-4568-AB46-2804BD99C60DQ37422818-2E7243B3-1B3B-448E-B83B-AED33C80CDFCQ37518057-D32B55F5-79B7-4AFB-AE2F-B3A71FFAF598Q37599583-1E3D9903-E902-460B-B7C5-0855B3311BE4Q37848651-468E042D-7AB4-4789-A9DC-C9F292ADBCBDQ37995056-7AFBFD94-301B-48AD-A040-DBC1A4013EABQ38163046-D62119C0-DB0E-4C51-8DD5-D29FE372DAEFQ38177871-1E4612CF-CFB4-4F2F-BB74-51DAA761B35EQ38181064-2E38287D-938D-418F-A9B3-92C1C4333D33Q38374486-AAACA110-BDD6-48F8-80F1-34589BD80E71Q38587671-3EE86830-86C0-4285-BB76-77FE396414E7
P2860
Measures in the first year of therapy predict the response to interferon β in MS
description
article
@en
im Juni 2009 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2009
@uk
name
Measures in the first year of therapy predict the response to interferon β in MS
@en
Measures in the first year of therapy predict the response to interferon β in MS
@nl
type
label
Measures in the first year of therapy predict the response to interferon β in MS
@en
Measures in the first year of therapy predict the response to interferon β in MS
@nl
prefLabel
Measures in the first year of therapy predict the response to interferon β in MS
@en
Measures in the first year of therapy predict the response to interferon β in MS
@nl
P2093
P2860
P50
P356
P1476
Measures in the first year of therapy predict the response to interferon beta in MS
@en
P2093
P2860
P304
P356
10.1177/1352458509104591
P577
2009-07-01T00:00:00Z